# THE ABCs OF MANAGING SMARTGUARD™ AUTO MODE

A Simple Approach



# A: ASSESS AUTO MODE

Auto Mode: Self-adjusting basal every 5 minutes to help your patients stay in target glucose range.<sup>1</sup>

# 4 Things to Assess for Success<sup>3</sup>:

■ Time in Range: > 70%²

Time in Auto Mode: ≥ 80%

■ Sensor Wear: ≥85%

Time Below Range: <4% time below 3.9 mmol/L</li>

<1% time below 3.0 mmol/L

ON	OFF			
7%	22%			
19%			> 13.9 mmol/L	
	34%		> 10 - 13.9 mmol/L	
73%	44% TIME IN		> 3.9-10.0 mmol/L	
RANGE	RANGE		< 3.9 mmol/L	
1%			< 3.0 mmol/L	
Stat	Statistics			
Auto	Mode (per	week)	97% (6d 18 hrs)	
Manu	al Mode (p	er week)	3% (5 hrs)	
Sense	or Wear (p	er week)	98% (6d 21 hrs)	

# **B**: BEHAVIORS



### **Meal Bolus:**

 Encourage patients to bolus 5-15 min BEFORE meals for best outcomes (unless glucose is low).



# **Correction Bolus:**

- Look for patient delivering pumprecommended correction boluses
- Discourage patient from entering phantom carbs to lower glucose faster as this may cause lows.



### Calibration:

Remind patients to calibrate the sensor 3-4 times daily. This keeps the sensor accurate and helps keep patients in Auto Mode.



## Follow-up:

- Instruct patient to upload to CareLink™ software regularly at home. If no computer access, advise to review time in range (TIR) graph weekly to assess TIR and time spent low (Options > History > Sensor Glucose Review).
- Set realistic expectations that follow-up may be more frequent during the first few weeks after starting Auto Mode.

# C: CLINICIAN CHANGES:



- Adjust insulin to carb ratio by 10-20% as needed
- Optimize carb ratios by looking for post-meal highs or lows using CareLink™ reports
- Adjust Manual Mode settings as needed, see reverse side



# THE ABCs OF MANAGING SMARTGUARD™ AUTO MODE

# A Simple Approach

# CLINICIAN ADJUSTMENT FOR MANUAL MODE SETTINGS3:

Once Auto Mode is initiated, the strategy for adjusting Manual Mode settings is to mirror Auto Mode settings as much as possible. It is recommended to use to a minimum of 3 weeks of Auto Mode data when evaluating the need for Manual Mode setting adjustment.

## Bolus Wizard™ BG Target:

5.6-8.3 mmol/L

# Insulin Sensitivity Factor (ISF):

Calculate ISF using the 100 Rule = 100/Total Daily Dose

### **Basal Rates:**

Take the average daily Auto Basal total (found in Statistics section of Assessment & Progress Report) and use one of these methods:

- Divide Auto Basal total by 24 hours and set one basal rate for Manual Mode
- Modify current Manual Mode basal rates proportionally to ensure the sum does not exceed the Auto Basal total
- If lows occur while in Manual Mode, decrease basal rate(s) by 10-20%

It is recommended to evaluate your patient's Manual Mode settings at each visit

#### IMPORTANT SAFETY INFORMATION: MINIMED™ 670G SYSTEM

The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable The MiniMed 670G system is intended for continuous delivery of basal insúlin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for  $the \, management \, of \, \bar{\textbf{T}} \text{ype} \, 1 \, diabetes \, mellitus \, in \, persons \, age \, \bar{\textbf{s}} \text{even and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and trending of glucose levels in the fluid properties of the continuous monitoring and the continuous monit$ under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM), and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3). For persons 7 to 13 years of age, sensor placement and insertion has been studied in the belly (abdomen) and buttock only and is not approved for other sites. For persons that are 14 years of age and older, sensor placement and insertion has been studied in the belly (abdomen) and back of upper arm only and is not approved for other sites.

WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump technology is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump technology is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed<sup>TM</sup> 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult www.medtronicdiabetes.ca and the appropriate user guide

#### IMPORTANT SAFETY INFORMATION: CARELINK™ SOFTWARE

The CareLink<sup>™</sup> software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into CareLink $^{\text{TM}}$  reports. The reports provide information that can be used to identify trends and track daily activities such as carbohydrates consumed, meal times, insulin delivery, and glucose readings. NOTE: CareLink<sup>TM</sup> report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. Patients should consult their healthcare providers familiar with the management of diabetes prior to making changes in diabetes management plan. For more details, please consult www.medtronicdiabetes.ca and the appropriate CareLink User Guide



 $<sup>^1</sup>$  Refers to Auto Mode. Some user interaction required. Individual results may vary.  $^2$  TIR  $\geq$  65% for ages 7-13 years.

<sup>&</sup>lt;sup>3</sup> Protocol for Hybrid Closed Loop Technology - MiniMed<sup>™</sup> 670G System - Medical Education